this won't be sold anytime soon! Gravy train has too much to give yet. They can/will chug along for years picking up their six figure salaries. Why would anyone use broker forecasts? They are always woefully incorrect. Even if they had an offer on the table they likely wouldn't tell shareholders..
well they keep saying about all the great products at their disposal. Shouldn't be a problem to sell lots of them then should it? Yes, exit from Taiwan would be good news for me too. It is a matter of when not if China invades!
one thing I noted from the presentation was the ref to 'last man standing' in the nipt arena. Roche and other big players have left the scene it seems. Hopefully leave the way clear for Ygen. They might see the nipt space as relatively small for their standards but it's big beans for Ygen. Anyway, must be good news that big players are leaving the scene imo.
'' I say mostly, because I think PR / RNSs can be better & more frequent. EG 12 newly installed NIPT labs (30% growth on base over last 6 months alone) why not announced and the other megalab (even if we have to respect client confidentiality''). GLT, I fully agree, why no PR/RNS with those good bits of news. Maybe because it's worth ferk all revenues and not material enough to bother. Even so it should have been relayed to investors on a RNS reach type of announcement imo.
Good job nobody takes ANY notice of Wallybroke...Have they EVER got anything correct? Certainly not where any forecast is concerned. Heaven knows why they carry on with them, cheap no doubt...and it shows, get rid asap imo. Does need some answers though!
can't they grasp that all they need to do is bloody well sell more of the wonderful products they keep telling us about. Rees continues to prove he's not up to the job, so maybe a new broom is needed. Forget about them trying to sell it.. too much gravy left yet! Surely there must be some good things to report ,....anyone? Can't watch it yet as not available.
'Ranger® Technology is applicable beyond NIPT and this disruptive technology can be applied to all types of DNA testing where automated size selection can bring considerable benefits to labs by enriching the DNA interest in a sample with considerable precision and speed. We have the unique opportunity to take advantage of multiple market segments, addressing needs in areas that use liquid biopsy (such as NIPT, oncology and infectious disease) as well as the gene synthesis and RNA size selection markets. We have a significant pipeline of opportunities for Ranger® Technology which are at various stages of feasibility and validation'.